Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HMBD-501
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Endeavor Biomedicines
Deal Size : $430.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s HMBD-501, a next-generation HER3-targeted antibody-drug conjugate (ADC).
Brand Name : HMBD-501
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 19, 2023
Lead Product(s) : HMBD-501
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Endeavor Biomedicines
Deal Size : $430.0 million
Deal Type : Licensing Agreement
Lead Product(s) : HMBD-001,Cetuximab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, Hummingbird will evaluate its potentially best-in-class HER3-targeting antibody, HMBD-001, in combination with SoC chemotherapy with or without Merck's cetuximab, anti-EGFR mAb, in patients with sqNSCLC in a Phase 1b clinical tri...
Brand Name : HMBD-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : HMBD-001,Cetuximab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : George Clinical
Deal Size : Undisclosed
Deal Type : Agreement
George Clinical to Support Hummingbird’s Phase 1 Oncology Trials
Details : George Clinical will provide its full-service CRO expertise for the Hummingbird sponsored trials, including HMBD-001, a unique antibody engineered to bind strongly and specifically to the dimerization interface of HER3, developed with its Rational Antibo...
Brand Name : HMBD-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 04, 2023
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : George Clinical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HMBD-001 is an anti-HER3 antibody in development that has the potential to fully block both ligand-dependent and independent HER3 activation and oncogenic signaling, by targeting a key epitope located at the interface where HER3 forms heterodimers with H...
Brand Name : HMBD-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 06, 2023
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Study Phase : Preclinical
Recipient : Synaffix
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Antibody-drug Conjugate-based Therapy
Therapeutic Area : Technology
Highest Development Status : Preclinical
Recipient : Synaffix
Deal Size : $150.0 million
Deal Type : Licensing Agreement
Lead Product(s) : HMBD-002,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HMBD-002 is an investigational IgG4 anti-VISTA antagonist antibody to target the region where VISTA interacts with binding partners that have been shown to play an important role in modulating T cell activity, potentially unlocking the immune system to a...
Brand Name : HMBD-002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 19, 2022
Lead Product(s) : HMBD-002,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HMBD-002,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under this collaboration, Hummingbird will evaluate the safety, tolerability, and anti-tumor activity of its novel anti-VISTA antibody, HMBD-002, in combination with KEYTRUDA ® (pembrolizumab).
Brand Name : HMBD-002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 25, 2021
Lead Product(s) : HMBD-002,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HMBD-001 is a novel antibody with a unique, differentiated mechanism of action that fully inhibits HER3 activation of the MAPK/PI3K tumor growth signaling pathway.
Brand Name : HMBD-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 02, 2021
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Novogene
Deal Size : Undisclosed
Deal Type : Partnership
Details : Partnership will leverage Novogene’s strong molecular diagnostics capabilities to expand patient identification through Next Generation Sequencing, NGS, testing in China to support the development of Hummingbird Bioscience’s investigational drug cand...
Brand Name : HMBD-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 09, 2021
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Novogene
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Novo Holdings
Deal Size : $125.0 million
Deal Type : Series C Financing
Hummingbird Bioscience Raises US$125 Million in Series C Financing
Details : Proceeds from the financing will be used to advance the clinical development of Hummingbird’s lead assets including, HMBD-001, a best-in-class HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, an anti-VISTA neutralizing antibody.
Brand Name : HMBD-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 18, 2021
Lead Product(s) : HMBD-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Novo Holdings
Deal Size : $125.0 million
Deal Type : Series C Financing
LOOKING FOR A SUPPLIER?